{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T18:01:42Z","timestamp":1790704902383,"version":"4.1.0"},"reference-count":165,"publisher":"Elsevier BV","issue":"13","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jacc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JACC"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.jacc.2026.06.015","type":"journal-article","created":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T14:31:30Z","timestamp":1784730690000},"page":"1503-1524","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Refining the Role of Beta-Blockers in Cardiovascular Medicine"],"prefix":"10.1016","volume":"88","author":[{"given":"Brett W.","family":"Sperry","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad","family":"Abdel Jawad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1278-6245","authenticated-orcid":false,"given":"Deepak L.","family":"Bhatt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wilfried","family":"Mullens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea M.","family":"Russo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1254-4860","authenticated-orcid":false,"given":"Randall C.","family":"Starling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jacc.2026.06.015_bib1","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1016\/S0140-6736(64)91275-9","article-title":"A new adrenergic","volume":"283","author":"Black","year":"1964","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2026.06.015_bib2","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1161\/01.CIR.101.5.558","article-title":"beta-adrenergic receptor blockade in chronic heart failure","volume":"101","author":"Bristow","year":"2000","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2026.06.015_bib3","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1002\/cpt1975185part1598","article-title":"Efficacy of beta adrenergic blockade in coronary heart disease: propranolol in angina pectoris","volume":"18","author":"Miller","year":"1975","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.jacc.2026.06.015_bib4","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.jacc.2025.12.002","article-title":"When do clinical trials expire?","volume":"87","author":"Krumholz","year":"2026","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2026.06.015_bib5","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.121.009120","article-title":"Hemodynamic effects of cyclic guanosine monophosphate-dependent signaling through \u03b23 adrenoceptor stimulation in patients with advanced heart failure: a randomized invasive clinical trial","volume":"15","author":"Bundgaard","year":"2022","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.jacc.2026.06.015_bib6","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1002\/ejhf.714","article-title":"The first-in-man randomized trial of a beta3 adrenoceptor agonist in chronic heart failure: the BEAT-HF trial","volume":"19","author":"Bundgaard","year":"2017","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.jacc.2026.06.015_bib7","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1038\/sj.bjp.0706048","article-title":"The selectivity of beta-adrenoceptor antagonists at the human \u03b21, \u03b22 and \u03b23 adrenoceptors","volume":"144","author":"Baker","year":"2005","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.jacc.2026.06.015_bib8","doi-asserted-by":"crossref","first-page":"2127","DOI":"10.1016\/j.jacc.2011.02.020","article-title":"Heart failure and chronic obstructive pulmonary disease the quandary of beta-blockers and beta-agonists","volume":"57","author":"Hawkins","year":"2011","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2026.06.015_bib9","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1002\/cpt.3351","article-title":"Clinical Pharmacogenetics Implementation Consortium guideline (CPIC) for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 genotypes and beta-blocker therapy","volume":"116","author":"Duarte","year":"2024","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.jacc.2026.06.015_bib10","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1111\/j.1365-2125.2006.02796.x","article-title":"The influence of CYP2D6 phenotype on the clinical response of nebivolol in patients with essential hypertension","volume":"63","author":"Lefebvre","year":"2007","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.jacc.2026.06.015_bib11","doi-asserted-by":"crossref","first-page":"11288","DOI":"10.1073\/pnas.0509937103","article-title":"A polymorphism within a conserved beta(1)-adrenergic receptor motif alters cardiac function and beta-blocker response in human heart failure","volume":"103","author":"Liggett","year":"2006","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jacc.2026.06.015_bib12","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1016\/j.jchf.2019.04.004","article-title":"Bucindolol for the maintenance of sinus rhythm in a genotype-defined HF population: the GENETIC-AF trial","volume":"7","author":"Piccini","year":"2019","journal-title":"JACC Heart Fail"},{"key":"10.1016\/j.jacc.2026.06.015_bib13","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1161\/CIRCHEARTFAILURE.109.885962","article-title":"An \u03b12C-adrenergic receptor polymorphism alters the norepinephrine-lowering effects and therapeutic response of the \u03b2-blocker bucindolol in chronic heart failure","volume":"3","author":"Bristow","year":"2010","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.jacc.2026.06.015_bib14","doi-asserted-by":"crossref","first-page":"1730","DOI":"10.1136\/bmj.318.7200.1730","article-title":"\u03b2 blockade after myocardial infarction: systematic review and meta regression analysis","volume":"318","author":"Freemantle","year":"1999","journal-title":"BMJ"},{"key":"10.1016\/j.jacc.2026.06.015_bib15","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1001\/2012.jama.11348","article-title":"Association of changes in clinical characteristics and management with improvement in survival among patients with ST-elevation myocardial infarction","volume":"308","author":"Puymirat","year":"2012","journal-title":"JAMA"},{"key":"10.1016\/j.jacc.2026.06.015_bib16","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1016\/j.jacc.2005.06.054","article-title":"Duration of ischemia is a major determinant of transmurality and severe microvascular obstruction after primary angioplasty","volume":"46","author":"Tarantini","year":"2005","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2026.06.015_bib17","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1161\/CIRCEP.110.959213","article-title":"Early reperfusion therapy affects inducibility, cycle length, and occurrence of ventricular tachycardia late after myocardial infarction","volume":"4","author":"Piers","year":"2011","journal-title":"Circ Arrhythm Electrophysiol"},{"key":"10.1016\/j.jacc.2026.06.015_bib18","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1093\/ehjcvp\/pvy034","article-title":"Effect of oral \u03b2-blocker treatment on mortality in contemporary post-myocardial infarction patients: a systematic review and meta-analysis","volume":"5","author":"Dahl Aarvik","year":"2019","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"10.1016\/j.jacc.2026.06.015_bib19","doi-asserted-by":"crossref","first-page":"2710","DOI":"10.1016\/j.jacc.2017.03.578","article-title":"\u03b2-Blockers and mortality after acute myocardial infarction in patients without heart failure or ventricular dysfunction","volume":"69","author":"Dondo","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2026.06.015_bib20","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1016\/j.amjmed.2014.05.032","article-title":"Clinical outcomes with \u03b2-blockers for myocardial infarction: a meta-analysis of randomized trials","volume":"127","author":"Bangalore","year":"2014","journal-title":"Am J Med"},{"key":"10.1016\/j.jacc.2026.06.015_bib21","doi-asserted-by":"crossref","first-page":"1901","DOI":"10.1056\/NEJMoa2505985","article-title":"Beta-blockers after myocardial infarction in patients without heart failure","volume":"393","author":"Munkhaugen","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2026.06.015_bib22","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1056\/NEJMoa2512686","article-title":"Beta-blockers after myocardial infarction with normal ejection fraction","volume":"394","author":"Kristensen","year":"2026","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2026.06.015_bib23","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1016\/j.ehj.2004.06.002","article-title":"Expert consensus document on \u03b2-adrenergic receptor blockers","volume":"25","author":"L\u00f3pez-Send\u00f3n","year":"2004","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2026.06.015_bib24","doi-asserted-by":"crossref","first-page":"2135","DOI":"10.1016\/j.jacc.2024.11.009","article-title":"2025 ACC\/AHA\/ACEP\/NAEMSP\/SCAI guideline for the management of patients with acute coronary syndromes: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"85","author":"Rao","year":"2025","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2026.06.015_bib25","doi-asserted-by":"crossref","first-page":"3720","DOI":"10.1093\/eurheartj\/ehad191","article-title":"2023 ESC guidelines for the management of acute coronary syndromes","volume":"44","author":"Byrne","year":"2023","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2026.06.015_bib26","doi-asserted-by":"crossref","first-page":"2048","DOI":"10.1016\/j.jacc.2017.06.032","article-title":"2017 AHA\/ACC clinical performance and quality measures for adults with ST-elevation and non\u2013ST-elevation myocardial infarction: a report of the American College of Cardiology\/American Heart Association Task Force on Performance Measures","volume":"70","author":"Jneid","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2026.06.015_bib27","doi-asserted-by":"crossref","first-page":"2504","DOI":"10.1016\/j.jacc.2025.02.001","article-title":"2025 AHA\/ACC clinical performance and quality measures for patients with chronic coronary disease: a report of the American College of Cardiology\/American Heart Association Joint Committee on Performance Measures","volume":"85","author":"Williams","year":"2025","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2026.06.015_bib28","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1056\/NEJM198104023041401","article-title":"Timolol-induced reduction in mortality and reinfarction in patients surviving acute myocardial infarction","volume":"304","year":"1981","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2026.06.015_bib29","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.1001\/jama.1982.03320370021023","article-title":"A randomized trial of propranolol in patients with acute myocardial infarction. I. Mortality results","volume":"247","year":"1982","journal-title":"JAMA"},{"key":"10.1016\/j.jacc.2026.06.015_bib30","first-page":"57","article-title":"Randomised trial of intravenous atenolol among 16 027 cases of suspected acute myocardial infarction: ISIS-1","volume":"2","year":"1986","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2026.06.015_bib31","first-page":"I26","article-title":"The G\u00f6teborg metoprolol trial. Effects on mortality and morbidity in acute myocardial infarction","volume":"67","author":"Hjalmarson","year":"1983","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2026.06.015_bib32","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1016\/S0140-6736(05)67661-1","article-title":"Early intravenous then oral metoprolol in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial","volume":"366","author":"Chen","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2026.06.015_bib33","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1161\/01.CIR.83.2.422","article-title":"Immediate versus deferred beta-blockade following thrombolytic therapy in patients with acute myocardial infarction. Results of the Thrombolysis in Myocardial Infarction (TIMI) II-B study","volume":"83","author":"Roberts","year":"1991","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2026.06.015_bib34","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1016\/S0140-6736(00)04560-8","article-title":"Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial","volume":"357","author":"Dargie","year":"2001","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2026.06.015_bib35","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1161\/01.CIR.0000108928.25690.94","article-title":"Effects of carvedilol on left ventricular remodeling after acute myocardial infarction: the CAPRICORN Echo SUBSTUDY","volume":"109","author":"Doughty","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2026.06.015_bib36","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1001\/jama.283.10.1295","article-title":"Effects of controlled-release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure: the Metoprolol CR\/XL Randomized Intervention Trial in Congestive Heart Failure (MERIT-HF)","volume":"283","author":"Hjalmarson","year":"2000","journal-title":"JAMA"},{"key":"10.1016\/j.jacc.2026.06.015_bib37","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1056\/NEJM199605233342101","article-title":"The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group","volume":"334","author":"Packer","year":"1996","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2026.06.015_bib38","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/S0140-6736(03)13800-7","article-title":"Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol or Metoprolol European Trial (COMET): randomised controlled trial","volume":"362","author":"Poole-Wilson","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2026.06.015_bib39","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/S0140-6736(98)11181-9","article-title":"The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial","volume":"353","year":"1999","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2026.06.015_bib40","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1161\/CIRCOUTCOMES.114.001073","article-title":"\u03b2-Blockers and cardiovascular events in patients with and without myocardial infarction: post hoc analysis from the CHARISMA trial","volume":"7","author":"Bangalore","year":"2014","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"10.1016\/j.jacc.2026.06.015_bib41","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0199347","article-title":"Long-term use of carvedilol in patients with ST-segment elevation myocardial infarction treated with primary percutaneous coronary intervention","volume":"13","author":"Watanabe","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.jacc.2026.06.015_bib42","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1056\/NEJMoa2504735","article-title":"Beta-blockers after myocardial infarction without reduced ejection fraction","volume":"393","author":"Ibanez","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2026.06.015_bib43","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1016\/S0140-6736(25)01592-2","article-title":"\u03b2 blockers after myocardial infarction with mildly reduced ejection fraction: an individual patient data meta-analysis of randomised controlled trials","volume":"406","author":"Rossello","year":"2025","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2026.06.015_bib44","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1093\/eurjpc\/zwae298","article-title":"Beta-blockers for secondary prevention following myocardial infarction in patients without reduced ejection fraction or heart failure: an updated meta-analysis","volume":"32","author":"Chi","year":"2025","journal-title":"Eur J Prev Cardiol"},{"key":"10.1016\/j.jacc.2026.06.015_bib45","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1056\/NEJMoa2401479","article-title":"Beta-blockers after myocardial infarction and preserved ejection fraction","volume":"390","author":"Yndigegn","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2026.06.015_bib46","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1016\/j.jacc.2023.04.003","article-title":"2023 AHA\/ACC\/ACCP\/ASPC\/NLA\/PCNA guideline for the management of patients with chronic coronary disease: a report of the American Heart Association\/American College of Cardiology Joint Committee on Clinical Practice Guidelines","volume":"82","author":"Virani","year":"2023","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2026.06.015_bib47","doi-asserted-by":"crossref","first-page":"3415","DOI":"10.1093\/eurheartj\/ehae177","article-title":"2024 ESC guidelines for the management of chronic coronary syndromes","volume":"45","author":"Vrints","year":"2024","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2026.06.015_bib48","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCOUTCOMES.117.004356","article-title":"Clinical events after discontinuation of \u03b2-blockers in patients without heart failure optimally treated after acute myocardial infarction: a cohort study on the French healthcare databases","volume":"11","author":"Neumann","year":"2018","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"10.1016\/j.jacc.2026.06.015_bib49","doi-asserted-by":"crossref","first-page":"3521","DOI":"10.1093\/eurheartj\/ehaa376","article-title":"Long-term \u03b2-blocker therapy and clinical outcomes after acute myocardial infarction in patients without heart failure: nationwide cohort study","volume":"41","author":"Kim","year":"2020","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2026.06.015_bib50","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1056\/NEJMoa2404204","article-title":"Beta-blocker interruption or continuation after myocardial infarction","volume":"391","author":"Silvain","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2026.06.015_bib51","doi-asserted-by":"crossref","first-page":"2894","DOI":"10.1093\/eurheartj\/ehaf170","article-title":"Beta-blocker interruption effects on blood pressure and heart rate after myocardial infarction: the A\u03b2YSS trial","volume":"46","author":"Procopi","year":"2025","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2026.06.015_bib52","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1056\/NEJMoa2601005","article-title":"Discontinuation of beta-blocker therapy after myocardial infarction","volume":"394","author":"Choi","year":"2026","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2026.06.015_bib53","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1016\/j.jcin.2016.05.048","article-title":"Predictors, trends, and outcomes (among older patients \u226565 years of age) associated with beta-blocker use in patients with stable angina undergoing elective percutaneous coronary intervention","volume":"9","author":"Motivala","year":"2016","journal-title":"JACC Cardiovasc Interv"},{"key":"10.1016\/j.jacc.2026.06.015_bib54","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1001\/jama.2012.12559","article-title":"\u03b2-Blocker use and clinical outcomes in stable outpatients with and without coronary artery disease","volume":"308","author":"Bangalore","year":"2012","journal-title":"JAMA"},{"key":"10.1016\/j.jacc.2026.06.015_bib55","first-page":"433","article-title":"Effects of the cardioselective beta-blocker metoprolol in angina pectoris. A subacute study with exercise tests","volume":"7","author":"Keyril\u00e4inen","year":"1975","journal-title":"Ann Clin Res"},{"key":"10.1016\/j.jacc.2026.06.015_bib56","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1016\/0002-8703(83)90037-6","article-title":"Double-blind randomized crossover trial of verapamil and propranolol in chronic stable angina","volume":"106","author":"Bowles","year":"1983","journal-title":"Am Heart J"},{"key":"10.1016\/j.jacc.2026.06.015_bib57","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1097\/00005344-198909000-00002","article-title":"Efficacy of controlled-release isosorbide-5-mononitrate as adjunctive treatment to beta-blocking agents in patients with stable angina pectoris","volume":"14","author":"Svendsen","year":"1989","journal-title":"J Cardiovasc Pharmacol"},{"key":"10.1016\/j.jacc.2026.06.015_bib58","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1016\/0140-6736(91)91900-F","article-title":"Efficacy of nifedipine and isosorbide mononitrate in combination with atenolol in stable angina","volume":"338","author":"Akhras","year":"1991","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2026.06.015_bib59","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1161\/01.CIR.103.12.1649","article-title":"Upregulation of \u03b23-adrenoceptors and altered contractile response to inotropic amines in human failing myocardium","volume":"103","author":"Moniotte","year":"2001","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2026.06.015_bib60","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1136\/hrt.37.10.1022","article-title":"Effect of chronic beta-adrenergic receptor blockade in congestive cardiomyopathy","volume":"37","author":"Waagstein","year":"1975","journal-title":"Br Heart J"},{"key":"10.1016\/j.jacc.2026.06.015_bib61","first-page":"1376","article-title":"report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines (Committee on Evaluation and Management of Heart Failure)","volume":"26","year":"1995","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2026.06.015_bib62","doi-asserted-by":"crossref","first-page":"e263","DOI":"10.1016\/j.jacc.2021.12.012","article-title":"2022 AHA\/ACC\/HFSA guideline for the management of heart failure: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"79","author":"Heidenreich","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2026.06.015_bib63","doi-asserted-by":"crossref","first-page":"3627","DOI":"10.1093\/eurheartj\/ehad195","article-title":"2023 focused update of the 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure","volume":"44","author":"McDonagh","year":"2023","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2026.06.015_bib64","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1016\/0140-6736(93)92930-R","article-title":"Beneficial effects of metoprolol in idiopathic dilated cardiomyopathy. Metoprolol in Dilated Cardiomyopathy (MDC) Trial Study Group","volume":"342","author":"Waagstein","year":"1993","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2026.06.015_bib65","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1016\/S0140-6736(05)79125-X","article-title":"3-year follow-up of patients randomised in the metoprolol in dilated cardiomyopathy trial. The Metoprolol in Dilated Cardiomyopathy (MDC) Trial Study Group","volume":"351","author":"Andersson","year":"1998","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2026.06.015_bib66","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1161\/01.CIR.90.4.1765","article-title":"A randomized trial of beta-blockade in heart failure. The Cardiac Insufficiency Bisoprolol Study (CIBIS)","volume":"90","year":"1994","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2026.06.015_bib67","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.cardfail.2003.08.003","article-title":"Do \u03b2-blockers prolong survival in heart failure only by inhibiting the \u03b21-receptor? A perspective on the results of the COMET trial","volume":"9","author":"Packer","year":"2003","journal-title":"J Card Fail"},{"key":"10.1016\/j.jacc.2026.06.015_bib68","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1093\/eurheartj\/ehi115","article-title":"Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS)","volume":"26","author":"Flather","year":"2005","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2026.06.015_bib69","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1093\/eurheartj\/ehi735","article-title":"Effects of nebivolol in elderly heart failure patients with or without systolic left ventricular dysfunction: results of the SENIORS echocardiographic substudy","volume":"27","author":"Ghio","year":"2006","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2026.06.015_bib71","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/S1388-9842(00)00120-3","article-title":"Effect of \u03b21 blockade with atenolol on progression of heart failure in patients pretreated with high-dose enalapril","volume":"2","author":"Sturm","year":"2000","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.jacc.2026.06.015_bib73","doi-asserted-by":"crossref","first-page":"f55","DOI":"10.1136\/bmj.f55","article-title":"Benefits of blockers in patients with heart failure and reduced ejection fraction: network meta-analysis","volume":"346","author":"Chatterjee","year":"2013","journal-title":"BMJ"},{"key":"10.1016\/j.jacc.2026.06.015_bib74","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1093\/eurheartj\/ehx564","article-title":"Beta-blockers for heart failure with reduced, mid-range, and preserved ejection fraction: an individual patient-level analysis of double-blind randomized trials","volume":"39","author":"Cleland","year":"2018","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2026.06.015_bib75","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1093\/eurheartj\/ehz158","article-title":"The continuous heart failure spectrum: moving beyond an ejection fraction classification","volume":"40","author":"Triposkiadis","year":"2019","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2026.06.015_bib76","doi-asserted-by":"crossref","first-page":"2235","DOI":"10.1016\/S0140-6736(14)61373-8","article-title":"Efficacy of \u03b2 blockers in patients with heart failure plus atrial fibrillation: an individual-patient data meta-analysis","volume":"384","author":"Kotecha","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2026.06.015_bib77","doi-asserted-by":"crossref","first-page":"1534","DOI":"10.1016\/j.jacc.2003.12.040","article-title":"Predischarge initiation of carvedilol in patients hospitalized for decompensated heart failure: results of the Initiation Management Predischarge: Process for Assessment of Carvedilol Therapy in Heart Failure (IMPACT-HF) trial","volume":"43","author":"Gattis","year":"2004","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2026.06.015_bib78","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1016\/S0140-6736(22)02076-1","article-title":"Safety, tolerability and efficacy of up-titration of guideline-directed medical therapies for acute heart failure (STRONG-HF): a multinational, open-label, randomised, trial","volume":"400","author":"Mebazaa","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2026.06.015_bib79","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1002\/ejhf.3732","article-title":"Heart failure improvement, remission, and recovery: A European Journal of Heart Failure expert consensus document","volume":"27","author":"Hulot","year":"2025","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.jacc.2026.06.015_bib80","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/S0140-6736(18)32484-X","article-title":"Withdrawal of pharmacological treatment for heart failure in patients with recovered dilated cardiomyopathy (TRED-HF): an open-label, pilot, randomised trial","volume":"393","author":"Halliday","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2026.06.015_bib81","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1016\/j.jchf.2025.02.022","article-title":"Carvedilol as single therapy for heart failure with improved ejection fraction: a randomized clinical trial (CATHEDRAL-HF)","volume":"13","author":"Belfort","year":"2025","journal-title":"JACC Heart Fail"},{"key":"10.1016\/j.jacc.2026.06.015_bib82","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1093\/eurheartj\/ehaf563","article-title":"Withdrawal of heart failure therapy after atrial fibrillation rhythm control with ejection fraction normalization: the WITHDRAW-AF trial","volume":"47","author":"Segan","year":"2026","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2026.06.015_bib83","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1016\/j.jacc.2020.01.040","article-title":"Withdrawal of neurohumoral blockade after cardiac resynchronization therapy","volume":"75","author":"Nijst","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2026.06.015_bib84","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/j.ahj.2007.06.002","article-title":"Effects of carvedilol early after myocardial infarction: analysis of the first 30 days in Carvedilol Post-Infarct Survival Control in Left Ventricular Dysfunction (CAPRICORN)","volume":"154","author":"Fonarow","year":"2007","journal-title":"Am Heart J"},{"key":"10.1016\/j.jacc.2026.06.015_bib85","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1016\/S0735-1097(98)00675-5","article-title":"Beta-adrenergic blocking agent use and mortality in patients with asymptomatic and symptomatic left ventricular systolic dysfunction: a post hoc analysis of the studies of left ventricular dysfunction","volume":"33","author":"Exner","year":"1999","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2026.06.015_bib86","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1161\/01.CIR.94.4.673","article-title":"Changes in early and late diastolic filling patterns induced by long-term adrenergic beta-blockade in patients with idiopathic dilated cardiomyopathy","volume":"94","author":"Andersson","year":"1996","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2026.06.015_bib87","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1093\/eurjhf\/hfr161","article-title":"Effects of the long-term administration of nebivolol on the clinical symptoms, exercise capacity, and left ventricular function of patients with diastolic dysfunction: results of the ELANDD study","volume":"14","author":"Conraads","year":"2012","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.jacc.2026.06.015_bib88","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1093\/eurjhf\/hfs141","article-title":"Effects of carvedilol on heart failure with preserved ejection fraction: the Japanese Diastolic Heart Failure Study (J-DHF)","volume":"15","author":"Yamamoto","year":"2013","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.jacc.2026.06.015_bib89","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2019.16598","article-title":"Association of \u03b2-blocker use with heart failure hospitalizations and cardiovascular disease mortality among patients with heart failure with a preserved ejection fraction: a secondary analysis of the TOPCAT trial","volume":"2","author":"Silverman","year":"2019","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.jacc.2026.06.015_bib90","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2025.29519","article-title":"\u03b2-Blocker use and health status among patients with heart failure with preserved ejection fraction","volume":"8","author":"Abdel Jawad","year":"2025","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.jacc.2026.06.015_bib91","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.amjcard.2024.01.023","article-title":"Association of beta-blocker use with exercise capacity in participants with heart failure with preserved ejection fraction: a post hoc analysis of the RELAX trial","volume":"216","author":"Patel","year":"2024","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacc.2026.06.015_bib92","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/j.jchf.2023.09.007","article-title":"Contemporary use and implications of beta-blockers in patients with HFmrEF or HFpEF","volume":"12","author":"Peikert","year":"2024","journal-title":"JACC Heart Fail"},{"key":"10.1016\/j.jacc.2026.06.015_bib93","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1016\/j.jchf.2023.03.017","article-title":"Beta-blocker use and heart failure outcomes in mildly reduced and preserved ejection fraction","volume":"11","author":"Arnold","year":"2023","journal-title":"JACC Heart Fail"},{"key":"10.1016\/j.jacc.2026.06.015_bib94","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1016\/j.cardfail.2021.04.015","article-title":"Association between \u03b2-blockers and outcomes in heart failure with preserved ejection fraction: current insights from the SwedeHF Registry","volume":"27","author":"Meyer","year":"2021","journal-title":"J Card Fail"},{"key":"10.1016\/j.jacc.2026.06.015_bib95","doi-asserted-by":"crossref","first-page":"2042","DOI":"10.1016\/j.jacc.2021.08.073","article-title":"Effect of \u03b2-blocker withdrawal on functional capacity in heart failure and preserved ejection fraction","volume":"78","author":"Palau","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2026.06.015_bib96","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1001\/jamacardio.2022.5320","article-title":"Effect of personalized accelerated pacing on quality of life, physical activity, and atrial fibrillation in patients with preclinical and overt heart failure with preserved ejection fraction: the myPACE randomized clinical trial","volume":"8","author":"Infeld","year":"2023","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.jacc.2026.06.015_bib97","doi-asserted-by":"crossref","first-page":"2893","DOI":"10.1093\/eurheartj\/ehad347","article-title":"Conventional heart failure therapy in cardiac ATTR amyloidosis","volume":"44","author":"Ioannou","year":"2023","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2026.06.015_bib98","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijcard.2024.131813","article-title":"Tolerability and effectiveness of beta-blockers in patients with cardiac amyloidosis: a systematic review and meta-analysis","volume":"402","author":"Kang","year":"2024","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.jacc.2026.06.015_bib99","article-title":"Transthyretin cardiac amyloidosis evaluation and management: 2025 ACC concise clinical guidance","author":"Kittleson","year":"2025","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2026.06.015_bib100","doi-asserted-by":"crossref","first-page":"2324","DOI":"10.1016\/j.jacc.2024.02.014","article-title":"2024 AHA\/ACC\/AMSSM\/HRS\/PACES\/SCMR guideline for the management of hypertrophic cardiomyopathy: a report of the American Heart Association\/American College of Cardiology Joint Committee on Clinical Practice Guidelines","volume":"83","author":"Ommen","year":"2024","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2026.06.015_bib101","doi-asserted-by":"crossref","first-page":"3503","DOI":"10.1093\/eurheartj\/ehad194","article-title":"2023 ESC guidelines for the management of cardiomyopathies","volume":"44","author":"Arbelo","year":"2023","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2026.06.015_bib102","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1056\/NEJMoa2504654","article-title":"Aficamten or metoprolol monotherapy for obstructive hypertrophic cardiomyopathy","volume":"393","author":"Garcia-Pavia","year":"2025","journal-title":"N Engl J Med"},{"issue":"25","key":"10.1016\/j.jacc.2026.06.015_bib103","first-page":"10070","article-title":"Effect of aficamten vs metoprolol on patient-reported health status in obstructive hypertrophic cardiomyopathy","volume":"S0735-1097","author":"Nassif","year":"2025","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2026.06.015_bib104","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1002\/ejhf.2737","article-title":"Effect of beta-blocker therapy on the response to mavacamten in patients with symptomatic obstructive hypertrophic cardiomyopathy","volume":"25","author":"Wheeler","year":"2023","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.jacc.2026.06.015_bib105","doi-asserted-by":"crossref","first-page":"2468","DOI":"10.1016\/j.jacc.2025.09.1575","article-title":"First-line therapy for hypertrophic cardiomyopathy: can\u2019t teach the old dogma new tricks","volume":"86","author":"Ibrahim","year":"2025","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2026.06.015_bib106","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1016\/j.jacc.2025.11.028","article-title":"Beta-blocker (bisoprolol) vs calcium-channel blocker (verapamil) in nonobstructive hypertrophic cardiomyopathy","volume":"87","author":"Bjerregaard","year":"2026","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2026.06.015_bib107","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.jacc.2023.08.017","article-title":"2023 ACC\/AHA\/ACCP\/HRS guideline for the diagnosis and management of atrial fibrillation: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"83","author":"Joglar","year":"2024","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2026.06.015_bib108","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1016\/j.jacc.2003.11.032","article-title":"The Atrial Fibrillation Follow-Up Investigation of Rhythm Management (AFFIRM) study","volume":"43","author":"Olshansky","year":"2004","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2026.06.015_bib109","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1001\/jama.2020.23138","article-title":"Effect of digoxin vs bisoprolol for heart rate control in atrial fibrillation on patient-reported quality of life: the RATE-AF randomized clinical trial","volume":"324","author":"Kotecha","year":"2020","journal-title":"JAMA"},{"key":"10.1016\/j.jacc.2026.06.015_bib110","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/j.ejheart.2006.01.015","article-title":"Presence and development of atrial fibrillation in chronic heart failure: experiences from the MERIT-HF Study","volume":"8","author":"van Veldhuisen","year":"2006","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.jacc.2026.06.015_bib111","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/S0735-1097(00)00693-8","article-title":"Use of metoprolol CR\/XL to maintain sinus rhythm after conversion from persistent atrial fibrillation: a randomized, double-blind, placebo-controlled study","volume":"36","author":"K\u00fchlkamp","year":"2000","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2026.06.015_bib112","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2020-038364","article-title":"Metoprolol for prophylaxis of postoperative atrial fibrillation in cardiac surgery patients: systematic review and meta-analysis","volume":"10","author":"Norhayati","year":"2020","journal-title":"BMJ Open"},{"key":"10.1016\/j.jacc.2026.06.015_bib113","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.jemermed.2015.01.014","article-title":"Diltiazem vs metoprolol in the management of atrial fibrillation or flutter with rapid ventricular rate in the emergency department","volume":"49","author":"Fromm","year":"2015","journal-title":"J Emerg Med"},{"key":"10.1016\/j.jacc.2026.06.015_bib114","first-page":"752","article-title":"Comparison of rate control efficacy between beta-blockers and calcium channel blockers in patients hospitalized with atrial fibrillation","volume":"24","author":"Sherf","year":"2022","journal-title":"Isr Med Assoc J"},{"key":"10.1016\/j.jacc.2026.06.015_bib115","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1001\/jama.2024.0076","article-title":"Diagnosis and management of paroxysmal supraventricular tachycardia","volume":"331","author":"Peng","year":"2024","journal-title":"JAMA"},{"key":"10.1016\/j.jacc.2026.06.015_bib116","doi-asserted-by":"crossref","first-page":"e27","DOI":"10.1016\/j.jacc.2015.08.856","article-title":"2015 ACC\/AHA\/HRS guideline for the management of adult patients with supraventricular tachycardia: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society","volume":"67","author":"Page","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2026.06.015_bib117","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1093\/eurheartj\/ehz467","article-title":"2019 ESC guidelines for the management of patients with supraventricular tachycardia. The Task Force for the management of patients with supraventricular tachycardia of the European Society of Cardiology (ESC)","volume":"41","author":"Brugada","year":"2020","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2026.06.015_bib118","doi-asserted-by":"crossref","first-page":"2194","DOI":"10.1161\/01.CIR.0000035653.72855.BF","article-title":"Effect of carvedilol on the morbidity of patients with severe chronic heart failure: results of the carvedilol prospective randomized cumulative survival (COPERNICUS) study","volume":"106","author":"Packer","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2026.06.015_bib119","doi-asserted-by":"crossref","first-page":"e91","DOI":"10.1016\/j.jacc.2017.10.054","article-title":"2017 AHA\/ACC\/HRS guideline for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death","volume":"72","author":"Al-Khatib","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2026.06.015_bib120","doi-asserted-by":"crossref","first-page":"2092","DOI":"10.1016\/j.jacc.2012.07.046","article-title":"Not All beta-blockers are equal in the management of long QT syndrome types 1 and 2","volume":"60","author":"Chockalingam","year":"2012","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2026.06.015_bib121","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1016\/j.jacc.2018.02.056","article-title":"Propranolol versus metoprolol for treatment of electrical storm in patients with implantable cardioverter-defibrillator","volume":"71","author":"Chatzidou","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2026.06.015_bib122","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1001\/jama.295.2.165","article-title":"Comparison of beta-blockers, amiodarone plus beta-blockers, or sotalol for prevention of shocks from implantable cardioverter defibrillators: the OPTIC Study: a randomized trial","volume":"295","author":"Connolly","year":"2006","journal-title":"JAMA"},{"key":"10.1016\/j.jacc.2026.06.015_bib123","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1001\/jama.1977.03270300059008","article-title":"Report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure. A cooperative study","volume":"237","year":"1977","journal-title":"JAMA"},{"key":"10.1016\/j.jacc.2026.06.015_bib124","volume":"Vol. 628","year":"1978"},{"key":"10.1016\/j.jacc.2026.06.015_bib125","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1016\/S0140-6736(02)08089-3","article-title":"Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint Reduction in Hypertension study (LIFE): a randomised trial against atenolol","volume":"359","author":"Dahl\u00f6f","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2026.06.015_bib126","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1016\/S0140-6736(05)67185-1","volume":"366","author":"Dahl\u00f6f","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2026.06.015_bib127","doi-asserted-by":"crossref","first-page":"2981","DOI":"10.1001\/jama.288.23.2981","volume":"288","year":"2002","journal-title":"JAMA"},{"key":"10.1016\/j.jacc.2026.06.015_bib128","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1016\/S0140-6736(05)67573-3","article-title":"Should beta-blockers remain first choice in the treatment of primary hypertension? A meta-analysis","volume":"366","author":"Lindholm","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2026.06.015_bib129","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1016\/S0140-6736(04)17355-8","article-title":"Atenolol in hypertension: is it a wise choice?","volume":"364","author":"Carlberg","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2026.06.015_bib130","article-title":"Beta-blockers for hypertension","volume":"2","author":"Wiysonge","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.jacc.2026.06.015_bib131","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2019.21618","article-title":"Comparison of cardiovascular events among users of different classes of antihypertension medications: a systematic review and network meta-analysis","volume":"3","author":"Wei","year":"2020","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.jacc.2026.06.015_bib132","doi-asserted-by":"crossref","first-page":"3912","DOI":"10.1093\/eurheartj\/ehae178","article-title":"2024 ESC guidelines for the management of elevated blood pressure and hypertension","volume":"45","author":"McEvoy","year":"2024","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2026.06.015_bib133","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1016\/j.jacc.2025.05.007","volume":"86","author":"Jones","year":"2025","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2026.06.015_bib134","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJM199612053352301","article-title":"Effect of atenolol on mortality and cardiovascular morbidity after noncardiac surgery","volume":"335","author":"Mangano","year":"1996","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2026.06.015_bib135","first-page":"633","article-title":"\u201cBisoprolol reduces cardiac death and myocardial infarction in high-risk patients as long as 2 years after successful major vascular surgery.\u201d","volume":"36","author":"Poldermans","year":"2015","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2026.06.015_bib136","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1016\/j.amjmed.2012.03.014","article-title":"Perioperative mischief: the price of academic misconduct","volume":"125","author":"Chopra","year":"2012","journal-title":"Am J Med"},{"key":"10.1016\/j.jacc.2026.06.015_bib137","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1016\/S0735-1097(01)01788-0","volume":"39","author":"Eagle","year":"2002","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2026.06.015_bib138","doi-asserted-by":"crossref","first-page":"2769","DOI":"10.1093\/eurheartj\/ehp337","article-title":"Guidelines for pre-operative cardiac risk assessment and perioperative cardiac management in noncardiac surgery","volume":"30","author":"Poldermans","year":"2009","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2026.06.015_bib139","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.1016\/S0140-6736(08)60601-7","article-title":"Effects of extended-release metoprolol succinate in patients undergoing noncardiac surgery (POISE trial): a randomised controlled trial","volume":"371","author":"Devereaux","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2026.06.015_bib140","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1136\/heartjnl-2013-304262","article-title":"Meta-analysis of secure randomised controlled trials of \u03b2-blockade to prevent perioperative death in noncardiac surgery","volume":"100","author":"Bouri","year":"2014","journal-title":"Heart"},{"key":"10.1016\/j.jacc.2026.06.015_bib141","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1016\/j.jacc.2024.06.013","article-title":"2024 AHA\/ACC\/ACS\/ASNC\/HRS\/SCA\/SCCT\/SCMR\/SVM guideline for perioperative cardiovascular management for noncardiac surgery: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"84","author":"Thompson","year":"2024","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2026.06.015_bib142","doi-asserted-by":"crossref","first-page":"3826","DOI":"10.1093\/eurheartj\/ehac270","article-title":"2022 ESC guidelines on cardiovascular assessment and management of patients undergoing noncardiac surgery","volume":"43","author":"Halvorsen","year":"2022","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2026.06.015_bib143","doi-asserted-by":"crossref","first-page":"e21","DOI":"10.1016\/j.jacc.2021.09.006","article-title":"2021 ACC\/AHA\/SCAI guideline for coronary artery revascularization","volume":"79","author":"Lawton","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2026.06.015_bib144","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1093\/eurheartj\/ehy394","article-title":"2018 ESC\/EACTS guidelines on myocardial revascularization","volume":"40","author":"Neumann","year":"2019","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2026.06.015_bib145","article-title":"Perioperative beta-blockers for preventing surgery-related mortality and morbidity in adults undergoing cardiac surgery","volume":"9","author":"Blessberger","year":"2019","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.jacc.2026.06.015_bib146","doi-asserted-by":"crossref","first-page":"e223","DOI":"10.1016\/j.jacc.2022.08.004","article-title":"2022 ACC\/AHA guideline for the diagnosis and management of aortic disease: a report of the American Heart Association\/American College of Cardiology Joint Committee on Clinical Practice Guidelines","volume":"80","author":"Isselbacher","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2026.06.015_bib147","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1001\/archinte.164.13.1389","article-title":"Adverse effects of \u03b2-blocker therapy for patients with heart failure: a quantitative overview of randomized trials","volume":"164","author":"Ko","year":"2004","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.jacc.2026.06.015_bib148","doi-asserted-by":"crossref","first-page":"1927","DOI":"10.1001\/jama.281.20.1927","article-title":"Meta-analysis of trials comparing beta-blockers, calcium antagonists, and nitrates for stable angina","volume":"281","author":"Heidenreich","year":"1999","journal-title":"JAMA"},{"key":"10.1016\/j.jacc.2026.06.015_bib149","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1093\/eurheartj\/eht429","article-title":"Calcium channel blockers improve exercise capacity and reduce N-terminal pro\u2013B-type natriuretic peptide levels compared with beta-blockers in patients with permanent atrial fibrillation","volume":"35","author":"Ulimoen","year":"2014","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2026.06.015_bib150","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1093\/ehjcvp\/pvae032","article-title":"Diltiazem reduces levels of NT-proBNP and improves symptoms compared with metoprolol in patients with permanent atrial fibrillation","volume":"10","author":"Enge","year":"2024","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"10.1016\/j.jacc.2026.06.015_bib151","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1056\/NEJMra1800345","article-title":"Treatment of hypertension in patients with asthma","volume":"381","author":"Christiansen","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2026.06.015_bib152","doi-asserted-by":"crossref","DOI":"10.3389\/fphys.2025.1582740","article-title":"An updated insight into the effect of \u03b2-adrenergic receptor antagonists (\u03b2-blockers) on respiratory function in asthma patients: a systematic review and meta-analysis","volume":"16","author":"Marko","year":"2025","journal-title":"Front Physiol"},{"key":"10.1016\/j.jacc.2026.06.015_bib153","doi-asserted-by":"crossref","first-page":"E172","DOI":"10.1093\/eurheartj\/suab116","article-title":"Certainties fading away: \u03b2-blockers do not worsen chronic obstructive pulmonary disease","volume":"23","author":"Verdecchia","year":"2021","journal-title":"Eur Heart J Supplements"},{"key":"10.1016\/j.jacc.2026.06.015_bib154","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1001\/jama.1992.03480130099032","article-title":"Beta-blockers and depression. Evidence against an association","volume":"267","author":"Bright","year":"1992","journal-title":"JAMA"},{"key":"10.1016\/j.jacc.2026.06.015_bib155","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1001\/jama.288.3.351","article-title":"\u03b2-Blocker therapy and symptoms of depression, fatigue, and sexual dysfunction","volume":"288","author":"Ko","year":"2002","journal-title":"JAMA"},{"key":"10.1016\/j.jacc.2026.06.015_bib156","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1007\/s10557-021-07197-9","article-title":"Effects of major antihypertensive drug classes on erectile function: a network meta-analysis","volume":"36","author":"Farmakis","year":"2022","journal-title":"Cardiovasc Drugs Ther"},{"key":"10.1016\/j.jacc.2026.06.015_bib157","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1111\/bcp.16361","article-title":"\u03b2-Blockers and risk of neuropsychiatric disorders: a systematic review and meta-analysis","volume":"91","author":"Eddin","year":"2025","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.jacc.2026.06.015_bib158","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1046\/j.1467-789X.2001.00044.x","article-title":"Use of beta-blockers in obesity hypertension: potential role of weight gain","volume":"2","author":"Pischon","year":"2001","journal-title":"Obes Rev"},{"key":"10.1016\/j.jacc.2026.06.015_bib159","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1016\/j.jpsychires.2025.06.029","article-title":"Exploring the association between beta-blockers use and sleep complaints in U.S. adults: an analysis of NHANES data (2011-2018)","volume":"189","author":"Liu","year":"2025","journal-title":"J Psychiatr Res"},{"key":"10.1016\/j.jacc.2026.06.015_bib160","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2025.29026","article-title":"First-line \u03b2-blocker use for hypertension in the Veterans Health Administration","volume":"8","author":"Derington","year":"2025","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.jacc.2026.06.015_bib161","doi-asserted-by":"crossref","first-page":"4460","DOI":"10.1111\/bcp.15442","article-title":"N-of-1 trials to facilitate evidence-based deprescribing: rationale and case study","volume":"88","author":"Goyal","year":"2022","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.jacc.2026.06.015_bib162","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.119.007012","article-title":"Polygenic score for \u03b2-blocker survival benefit in european ancestry patients with reduced ejection fraction heart failure","volume":"13","author":"Lanfear","year":"2020","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.jacc.2026.06.015_bib163","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCGEN.121.003835","article-title":"Validation of a polygenic score for beta-blocker survival benefit in patients with heart failure using the United Kingdom Biobank","volume":"16","author":"Lanfear","year":"2023","journal-title":"Circ Genom Precis Med"},{"key":"10.1016\/j.jacc.2026.06.015_bib164","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1002\/cpt.2355","article-title":"Adverse cardiovascular outcomes and antihypertensive treatment: a genome-wide interaction meta-analysis in the International Consortium for Antihypertensive Pharmacogenomics Studies","volume":"110","author":"McDonough","year":"2021","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.jacc.2026.06.015_bib165","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1016\/S0140-6736(21)01638-X","article-title":"Redefining \u03b2-blocker response in heart failure patients with sinus rhythm and atrial fibrillation: a machine learning cluster analysis","volume":"398","author":"Karwath","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2026.06.015_bib166","doi-asserted-by":"crossref","first-page":"3314","DOI":"10.1093\/eurheartj\/ehae176","article-title":"2024 ESC guidelines for the management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS)","volume":"45","author":"van Gelder","year":"2024","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2026.06.015_bib167","doi-asserted-by":"crossref","first-page":"3997","DOI":"10.1093\/eurheartj\/ehac262","article-title":"2022 ESC guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death","volume":"43","author":"Zeppenfeld","year":"2022","journal-title":"Eur Heart J"}],"container-title":["JACC"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S073510972606835X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S073510972606835X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T17:52:52Z","timestamp":1790704372000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S073510972606835X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":165,"journal-issue":{"issue":"13","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["S073510972606835X"],"URL":"https:\/\/doi.org\/10.1016\/j.jacc.2026.06.015","relation":{},"ISSN":["0735-1097"],"issn-type":[{"value":"0735-1097","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Refining the Role of Beta-Blockers in Cardiovascular Medicine","name":"articletitle","label":"Article Title"},{"value":"JACC","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacc.2026.06.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 by the American College of Cardiology Foundation. Published by Elsevier.","name":"copyright","label":"Copyright"}]}}